Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 3 2000
Play
Audio Below:
I
think its entirely conceivable that Arimidex will prove to be as
effective as tamoxifen in the adjuvant setting and, what is more
intriguing to me is this notion of combined therapy. There’s
no reason to speculate antagonism between these two approaches and
we – for example at Memorial – are exploring in a quite
different setting, in a chemoprevention pilot, the combined use
of selective estrogen receptor modulator and aromatase inactivator.
So these strategies are certainly worthy of exploration, and it
is to me conceivable that five or ten years from now standard adjuvant
therapy will not be one antiendocrine approach but a multi-pronged
approach.
Relevant
Articles:
Future
directions in endocrine treatment of advanced breast cancer. Bland
KI. Annals of Surgical Oncology. 6(8 Suppl S):14S-16S, 1999 Dec.
No Abstract
